207 related articles for article (PubMed ID: 34750662)
1. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
[TBL] [Abstract][Full Text] [Related]
2. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
Li XS; Li JW; Li H; Jiang T
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers.
Sun J; Hu S; Li X
Biomarkers; 2023 Sep; 28(6):477-485. PubMed ID: 37017446
[TBL] [Abstract][Full Text] [Related]
5. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
7. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
8. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
Front Immunol; 2018; 9():2077. PubMed ID: 30254644
[No Abstract] [Full Text] [Related]
11. Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis.
Li X; Zheng Y; Yue F
Target Oncol; 2021 Jan; 16(1):13-26. PubMed ID: 33222017
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis.
Ding Y; Sun C; Li J; Hu L; Li M; Liu J; Pu L; Xiong S
Scand J Immunol; 2017 Nov; 86(5):361-367. PubMed ID: 28930374
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis.
Huang P; Hu W; Zhu Y; Wu Y; Lin H
Front Oncol; 2020; 10():626932. PubMed ID: 33718120
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.
Ding Y; Sun C; Hu L; Xiong S; Zhai Z
Ann Hematol; 2023 Sep; 102(9):2425-2434. PubMed ID: 37382610
[TBL] [Abstract][Full Text] [Related]
15. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization.
Ma XL; Qu XD; Yang WJ; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Clin Chim Acta; 2020 Dec; 511():67-74. PubMed ID: 32979338
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
Wei W; Xu B; Wang Y; Wu C; Jiang J; Wu C
Medicine (Baltimore); 2018 Jan; 97(3):e9617. PubMed ID: 29504990
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
18. The predictive role of soluble programmed death ligand 1 in digestive system cancers.
Ruan J; Zhao Z; Qian Y; Xu R; Liao G; Kong FS
Front Oncol; 2023; 13():1170220. PubMed ID: 37519785
[TBL] [Abstract][Full Text] [Related]
19. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
[TBL] [Abstract][Full Text] [Related]
20. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]